FDA Rejection Delays Regeneron From Competing With J&J, Pfizer in Multiple Myeloma
globalreutersAugust 21, 20241 Mins read 
Regeneron Pharmaceuticals said the FDA cited no approvability concerns for its multiple myeloma drug, linvoseltamab, other than previously identified issues with a contract manufacturer. While linvoseltamab trails bispecific antibodies currently marketed by Johnson & Johnson and Pfizer, if approved, it could bring patients an earlier treatment option.
The post FDA Rejection Delays Regeneron From Competing With J&J, Pfizer in Multiple Myeloma appeared first on MedCity News.
Related Articles
When It Comes to AI, Rural Doctors Have FOMO — Meditech & Suki Are Teaming Up to Address This
Meditech is integrating Suki’s AI assistant into more than a dozen rural...
FTC to sue PBMs over insulin pricing and rebates
From the FTC’s press release out today: Today, the Federal Trade Commission...
World Mental Health Day 2024
Every year, World Mental Health Day is an opportunity for mental health...
North Carolina’s Effort to Relieve Medical Debt
This policy watch examines the burden of medical debt in North Carolina...
Leave a comment